| Budget Amount *help |
¥27,430,000 (Direct Cost: ¥21,100,000、Indirect Cost: ¥6,330,000)
Fiscal Year 2011: ¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2010: ¥9,490,000 (Direct Cost: ¥7,300,000、Indirect Cost: ¥2,190,000)
Fiscal Year 2009: ¥14,170,000 (Direct Cost: ¥10,900,000、Indirect Cost: ¥3,270,000)
|
|---|
| Research Abstract |
We identified the novel EMT inducible transcriptional factor associated with the metastasis/invasion of ovarian cancer. Of these, ALX-1 and PLAG2positively influenced the formation of peritoneal metastasis. Furthermore, in drug-refractory ovarian cancer model, we clarified the novel mechanism via microRNA(miR-200c) in the link between enhanced metastatic capability and EMT. Furthermore, it was demonstrated that EMT in mesothelial cells, as well as carcinoma cells also play acrucial role in the development of peritoneal dissemination. Our current study suggested the EMT inducible factor targeting therapy may lead to a new approach for the treatment of progression to the peritoneum and drug-resistance of ovarian cancer.
|
